New Immunotherapy Agent Reduces Disease Progression Risk in Gastric CancersJune 15th 2016
Findings for the new immunotherapy agent targeting claudin18.2 (CLDN18.2) presented at the 2016 ASCO Annual Meeting raised the possibility of a new therapeutic agent in a tumor type with relatively few current options. When added to standard chemotherapy, the treatment reduced the risk of death or disease progression by approximately 50% for patients with CLDN18.2-positive advanced gastric cancers.
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 MutationJune 8th 2016
Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Selective FGFR Inhibitor Shows Promise in Gastric and Breast CancersJune 4th 2016
Gastric cancers with high-level clonal FGFR2 gene amplification responded to AZD4547, a selective FGFR inhibitor, in a phase II open label trial of previously treated, advanced FGFR amplified cancer. Yet tumors with multiple FGFR1 genes, low level or subclonal amplification of FGFR2 did not respond similarly to the drug.
Pessimism Surrounds VEGF Inhibitors in Advanced Gastric CancerMay 26th 2016
When a recent trial found that apatinib, an experimental VEGFR inhibitor, met its clinical endpoint and showed efficacy as a third-line therapy in treating advanced refractory stomach cancer, one might have expected at least two cheers. After all, gastric cancer is the third most fatal form of the disease globally, and there is currently no standard third-line treatment for advanced patients.
H Pylori Eradication Reduces Gastric Cancer Incidence in High-Risk PopulationsMay 26th 2016
A meta-analysis found that treatment of the bacterium H pylori with antibiotics in a population at high risk for stomach cancer is associated with a reduced incidence rate of stomach cancer.
The Link Between Helicobacter Pylori and Gastric CancerMay 26th 2016
Keith T. Wilson, MD, Thomas F. Frist, Sr. Chair in Medicine, Professor, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center explains the link between helicobacter pylori (H pylori) and gastric cancer.
Higher Dose Trastuzumab Shows No Significant Impact on Survival in Gastric CancerMay 26th 2016
While the ToGA study showed a survival benefit with trastuzumab plus chemotherapy in HER2-positive gastric cancer, the drug proved no more efficacious when given in larger doses, according to Manish Shah, MD.
Olaparib Misses OS Endpoint in Phase III Gastric Cancer StudyMay 19th 2016
A phase III study exploring the combination of olaparib and paclitaxel missed its primary endpoint of improvement in overall survival compared with paclitaxel and placebo for patients with advanced gastric cancer.
Dr. Al-Batran on FLOT Benefit in Gastric CancerOctober 8th 2015
Salah-Eddin Al-Batran, MD, Medical Oncologist and Director, The Institute of Clinical Cancer Research and Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany discusses neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU in patients with locally advanced, resectable gastric/esophagogastric junction cancer.
A Little STING May Enhance the Immune System Against CancerApril 25th 2015
Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.
Expert Investigators Discuss Emerging Therapies for GI CancersFebruary 11th 2015
A panel of expert clinical investigators discussed details of several treatments and a dozen patient cases involving gastric, colorectal, and pancreatic cancer at a satellite meeting of the 2015 ASCO GI Cancers Symposium.
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic CancerJanuary 28th 2015
Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Ramucirumab Plus Paclitaxel Gains Approval for Advanced Gastric CancerNovember 7th 2014
Based on data from the phase III RAINBOW trial, the FDA has approved ramucirumab (Cyramza) in combination with paclitaxel as a treatment for patients with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.